Antihemophilic Factor Porcine Sequence Recombinant Brand Name– OBIZUR
What is Antihemophilic Factor Porcine Sequence Recombinant
Antihemophilic factor, porcine sequence, recombinant is an antihemophilic factor for the treatment of bleeding episodes in adults with acquired hemophilia A.
This product is expressed in a genetically engineered baby hamster kidney (BHK) cell line which secretes recombinant porcine factor VIII into the cell culture medium.
The recombinant porcine factor VIII protein is then purified utilizing a series of chromatography and filtration steps, including 2 dedicated viral clearance steps. No additives of human or animal origin are used in the formulation of this product.
Porcine factor VIII is used because it is similar to human factor VIII but less likely to be affected by the antibodies against human factor VIII that are present in acquired hemophilia A. Formation of porcine factor VIII antibodies can occur.
Antihemophilic factor, porcine sequence, recombinant was FDA-approved in October 2014.
- acquired hemophilia
- hemophilia A
For the treatment of bleeding episodes in adults with acquired hemophilia A
- anaphylactoid reactions
- antibody formation
- clotting inhibitor titers
- factor VIII concentrations
- factor VIII inhibitors
- hamster protein hypersensitivity
- Factor VIIa, Recombinant